Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX plus apatinib conversion therapy for locally advanced or metastatic gastric cancer
ChiCTR-OPC-17012564Phase 4Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, tegafur and oxaliplatin in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: R0 resection rate and Pathological remission rate. Started Sep 2017; status: recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-17012564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012564.